Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC-201 Maintenance Therapy in AML and MDS After Stem Cell Transplant
NCT03932643Phase 1Completed
- Sponsor
- University of Nebraska
- Start
- Jul 2019
- Primary completion
- Mar 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dordaviprone in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Nebraska. Primary endpoints: Rate of dose limiting toxicities at 1 month and Grade >=3 toxicities at 3 months. Started Jul 2019; status: completed.
02
Drugs
dordaviprone
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03932643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932643.